{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000645","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-05-19T11:00:48+00:00","discovered_at":"2026-05-19T11:05:00.245319+00:00","generated_at":"2026-05-19T11:05:58.604313+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts","bullets":["Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.","Bonney brings 30+ years biopharma experience, including Avonex launch at Biogen and CEO of Cubist (acquired by Merck for $9.5B).","Board size increased from 9 to 10; Bonney received option grant for 100k shares vesting over 3 years.","Company advances vidofludimus calcium toward phase 3 ENSURE readout in relapsing MS and planned PPMS program.","Simona Skerjanec remains as board member after transitioning from Interim Chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000645","json":"https://secwatch.observer/filing/0001193805-26-000645.json","markdown":"https://secwatch.observer/filing/0001193805-26-000645.md","text":"https://secwatch.observer/filing/0001193805-26-000645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/0001193805-26-000645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/e665479_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T11:05:58.604313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e16decec2","claim":"Simona Skerjanec changed role as Member of the Board at IMMUNIC, INC..","evidence_excerpt":"Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/0001193805-26-000645-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned from Interim Chairperson"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"73ffb4f423","claim":"Michael W. Bonney was appointed as Chair of the Board at IMMUNIC, INC..","evidence_excerpt":"appointed Michael W. Bonney as Chair of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/0001193805-26-000645-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}